The Microbicide Development Program (MDP) based at UCLA will be composed of a cohesive group of clinical, basic and behavioral scientists, and support staff focused on acquiring and assembling an integrated database of physiologic, pathophysiologic, immunologic, virologic, behavioral and acceptability responses that contribute to the development of i_ topical rectal HIV microbicide. The Administrative Core will have the primary goals of facilitating interactions in a smooth and effective manner, providing a reliable infrastructure for fiscal management of the program, provide ongoing ommunications with NIH and the Project Officer as well as the Scientific Advisory Panel (SAP) appointed by NIH. Most importantly, the Core will (i) provide a focus for efficient leadership of the overall MDP Project by facilitating communication between Executive Committee (EC) members, Project investigators and staff and (ii) provide the forum for emergence of synergistic results and interpretations from each Project. The Administrative Core Mll support the broad array of investigators and their unique research, fiscal, communication, and general administrative needs adapting and responding to all the stakeholders as the MDP grows and evolves in its efforts to develop a safe and effective topical HIV microbicide.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
3U19AI060614-05S1
Application #
7979338
Study Section
Special Emphasis Panel (ZRG1-AARR-A (51))
Project Start
2009-09-18
Project End
2010-07-31
Budget Start
2009-09-18
Budget End
2010-07-31
Support Year
5
Fiscal Year
2009
Total Cost
$80,728
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Chiu, Wai Kan; Brand, Rhonda M; Camp, Danielle et al. (2017) The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants. AIDS Res Hum Retroviruses 33:820-826
Leyva, Francisco; Fuchs, Edward J; Bakshi, Rahul et al. (2015) Simultaneous Evaluation of Safety, Acceptability, Pericoital Kinetics, and Ex Vivo Pharmacodynamics Comparing Four Rectal Microbicide Vehicle Candidates. AIDS Res Hum Retroviruses 31:1089-97
Preza, Gloria Cuevas; Yang, Otto O; Elliott, Julie et al. (2015) T lymphocyte density and distribution in human colorectal mucosa, and inefficiency of current cell isolation protocols. PLoS One 10:e0122723
Yang, Otto O; Ibarrondo, F Javier; Price, Charles et al. (2014) Differential blood and mucosal immune responses against an HIV-1 vaccine administered via inguinal or deltoid injection. PLoS One 9:e88621
Yang, Kuo-Hsiung; Hendrix, Craig; Bumpus, Namandje et al. (2014) A multi-compartment single and multiple dose pharmacokinetic comparison of rectally applied tenofovir 1% gel and oral tenofovir disoproxil fumarate. PLoS One 9:e106196
Richardson-Harman, Nicola; Hendrix, Craig W; Bumpus, Namandjé N et al. (2014) Correlation between compartmental tenofovir concentrations and an ex vivo rectal biopsy model of tissue infectibility in the RMP-02/MTN-006 phase 1 study. PLoS One 9:e111507
Gorbach, Pamina M; Pines, Heather; Javanbakht, Marjan et al. (2014) Order of orifices: sequence of condom use and ejaculation by orifice during anal intercourse among women: implications for HIV transmission. J Acquir Immune Defic Syndr 67:424-9
Pines, Heather A; Gorbach, Pamina M; Weiss, Robert E et al. (2013) Acceptability of potential rectal microbicide delivery systems for HIV prevention: a randomized crossover trial. AIDS Behav 17:1002-15
Leyva, Francisco J; Bakshi, Rahul P; Fuchs, Edward J et al. (2013) Isoosmolar enemas demonstrate preferential gastrointestinal distribution, safety, and acceptability compared with hyperosmolar and hypoosmolar enemas as a potential delivery vehicle for rectal microbicides. AIDS Res Hum Retroviruses 29:1487-95
Anton, Peter A; Cranston, Ross D; Kashuba, Angela et al. (2012) RMP-02/MTN-006: A phase 1 rectal safety, acceptability, pharmacokinetic, and pharmacodynamic study of tenofovir 1% gel compared with oral tenofovir disoproxil fumarate. AIDS Res Hum Retroviruses 28:1412-21

Showing the most recent 10 out of 35 publications